Beacon Biosignals' EEG neurobiomarker platform is developed to discover and scale new clinical paradigms for patients with psychiatric and neurological diseases.
FREMONT, CA: Cyclerion Therapeutics and Beacon Biosignals have announced an expanded and extended strategic partnership between the two companies. This partnership is expected to recognize disease-relevant biomarkers to refine patient selection and endpoints to guide the clinical development of Cyclerion's investigational therapeutics for neurological diseases associated with cognitive impairment.
Beacon Biosignals' EEG neurobiomarker platform is developed to discover and scale new clinical paradigms for patients with psychiatric and neurological diseases. Beacon Biosignals combines a world-class clinical electroencephalogram (EEG) database with unique, AI-based algorithms and analytical capabilities to uncover neurological biomarkers of pharmacological action and efficacy. Different EEG patterns are linked to neurodevelopmental status and a variety of neurological illnesses, and neurologically active treatments can influence them. To help overcome the challenges of transferring PK/PD models from preclinical animal investigations, the platform immediately evaluates these effects and informs dose selection in people.
Beacon Biosignals and Cyclerion previously worked together to analyze data from a Cyclerion clinical translational pharmacology trial of CY6463, which showed clear impacts on EEG measures linked with aging and disease. These findings were recently presented at the American Academy of Neurology's annual meeting (Glasser et al., 2021). Incorporating the Beacon Biosignals technique into ongoing and planned Cyclerion patient trials is intended to benefit the Company's primary clinical product, CY6463, as well as CY3018, a next-generation preclinical program, in their continuing clinical development.
CY6463 is an oral, first-in-class CNS-penetrant sGC stimulator being developed for neurological illnesses linked with cognitive impairment. CY6463 was created to target numerous pathophysiological characteristics of neurodegenerative and neuropsychiatric illnesses that cause cognitive impairment. Initial CY6463 clinical tests revealed acceptable safety and tolerability and pharmacologically appropriate drug exposure in the cerebral spinal fluid. Furthermore, CY6463 showed promising effects on EEG, neuroinflammation, and other neurophysiological measurements, indicating that it should be studied further.
